1. ALLA AKTIER
  2. NYHETER
  3. Q-LINEA

Q-Linea

Nyheter Q-Linea Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Q-linea announces changes in executive leadership team

MARKN.

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) today announces that Natalie Brown has been appointed Director Global Marketing and will join the Executive Management Group as of July 1, 2025. The company also announces the departure of Karl Sköld, Director System & Support.

Natalie will lead the global marketing activities and work closely with the commercial teams in the US and in EMEA. Natalie will continue to be based in the US.

“Natalie brings a wealth of experience to the Q-linea team, and her expanded role will elevate the conversation within the Executive Management Group”, says Q-linea CEO Stuart Gander.

Director System & Support Karl Sköld will leave Q-linea mid-June after transitioning responsibilities within the executive team. “I would like to extend my gratitude for the leadership and expertise provided by Karl who has supported our journey for seven years across a variety of domains and leadership roles”, says Stuart.

Q-linea is a leader in rapid antimicrobial susceptibility testing (rAST). “I am excited to build on the strong foundation established by the commercial teams in the US and in EMEA and look forward to accelerating our global growth trajectory”, says Natalie Brown.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea announces changes in executive leadership team

Datum 2025-04-28, kl 16:23
Källa MFN
Bifogade filer
Q-linea announces changes in executive leadership team